# Fibrotic Interstitial Lung Disease Early Recognition and Strategic Therapy Study in China

> **NCT06655090** · — · RECRUITING · sponsor: **Dai Huaping** · enrollment: 10000 (estimated)

## Conditions studied

- Interstitial Lung Disease (ILD)

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT06655090
- **Lead sponsor:** Dai Huaping
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2021-12-01
- **Primary completion:** 2024-11-30
- **Final completion:** 2027-11-30
- **Target enrollment:** 10000 (ESTIMATED)
- **Last updated:** 2024-10-23

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06655090

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06655090, "Fibrotic Interstitial Lung Disease Early Recognition and Strategic Therapy Study in China". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06655090. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*